Ayşe Betül Dere

Dr. Ayşe Betül Dere

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 September 2026 in Annals of Nuclear Medicine
Verified
Journal Article
Closed access
PDF file
EKEnes Mustafa Kaya
Enes Mustafa Kaya
BABurcu Esen Akkas
Burcu Esen Akkas
TGTevfik Güzelbey
Tevfik Güzelbey
ÇEÇağrı Erdim
Çağrı Erdim
MAMustafa Fatih Arslan
Mustafa Fatih Arslan
MKMeryem Kaya
Meryem Kaya

5 September 2026 in EJNMMI Research
Verified
Journal Article
Open access
PDF file
EKEnes Mustafa Kaya
Enes Mustafa Kaya
BABurcu Esen Akkas
Burcu Esen Akkas
ÇEÇağrı Erdim
Çağrı Erdim
ADAli Dablan
Ali Dablan
MAMustafa Fatih Arslan
Mustafa Fatih Arslan
MKMeryem Kaya
Meryem Kaya
To evaluate the relative contribution of the 400 Gy perfused liver absorbed dose (PLAD) threshold and tumor size in predicting complete response (

15 October 2026 in Diagnostics
Verified
Journal Article
Open access
PDF file
HOHalim Ozcevik
Halim Ozcevik
EKEnes Mustafa Kaya
Enes Mustafa Kaya
BABurcu Esen Akkas
Burcu Esen Akkas
GBGündüzalp Buğrahan Babacan
Gündüzalp Buğrahan Babacan
ADAyşe Betül Dere
Ayşe Betül Dere
MKMeryem Kaya
Meryem Kaya
Background/Objectives: Current guidelines define no absolute contraindication to prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT), yet some patients receive only a single cycle. We aimed to characterize this single-cycle attrition (SCA) and derive an exploratory pretreatment risk score predicting it. Methods: Seventy consecutive patients with metastatic castration-resistant prostate cancer treated with [177Lu]Lu-PSMA RLT at one center (2022–2025) were reviewed; 58 were assessable. SCA was defined as permanent non-initiation of a second cycle. The analyses employed false-discovery-rate-adjusted nonparametric comparisons, receiver operating characteristic (ROC), Kaplan–Meier and univariable Cox methods, with optimism-corrected bootstrap internal validation. Results: SCA occurred in 12 of 58 patients (20.7%), owing to death or rapid clinical deterioration (n = 8) or grade 3–4 hematotoxicity (n = 4); all 12 died (median overall survival 3 months). Higher C-reactive protein (CRP), lower lymphocytes and hemoglobin, and higher alkaline phosphatase (ALP) and prostate-specific antigen (PSA) separated the groups (all q < 0.05). The five-item Single-Cycle Attrition Risk (SCAR-5) score (one point each: CRP ≥ 16.5 mg/L, lymphocytes ≤ 1.39 × 109/L, hemoglobin ≤ 9.6 g/dL, ALP ≥ 191 U/L, PSA ≥ 34.2 ng/mL) discriminated SCA with an optimism-corrected area under the ROC curve (AUC) of 0.88 (apparent AUC 0.95, 95% confidence interval (CI) 0.89–0.99). No SCA occurred below score 3 (0/39; upper 95% confidence limit 9.0%); a score ≥ 3 identified all events (sensitivity 100%, 95% CI 74–100; specificity 85%, 95% CI 71–94) and was associated with shorter survival (univariable Cox hazard ratio 3.94, 95% CI 2.01–7.74). Conclusions: One in five patients who initiated RLT did not proceed beyond the first cycle. SCAR-5, an exploratory score derived from routine pretreatment laboratory values, stratified risk of early treatment attrition; external prospective validation is required before clinical use.